Author

Jen-Fue Maa 1

1 AbbVie Inc, North Chicago, United States of America

ASSESSMENT OF IMPACT III WELL-BEING DOMAIN SCORES IN ADALIMUMAB-TREATED PAEDIATRIC PATIENTS WITH CROHN'S DISEASE

Amy Grant, Anthony R. Otley, Johanna Caroline Escher, Jeffrey S Hyams, Jen-Fue Maa, Gabriela Alperovich, Andreas Lazar, Anne M. Robinson, Anthony W. Wang, Samantha Eichner

CORRELATION BETWEEN ENDOSCOPIC AND HISTOLOGICAL HEALING IN ADULTS WITH MODERATE TO SEVERE CROHN?S DISEASE: DATA FROM EXTEND

Walter Reinisch, Jean-Frederic Colombel, Paul Rutgeerts, Karel Geboes, Geert R. D'Haens, Joel Petersson, Samantha Eichner, Jen-Fue Maa, Anne M. Robinson

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt, Geert R. D'Haens, Remo Panaccione, William Sandborn, Walter Reinisch, Simon Travis, Stefan Schreiber, Alessandro Armuzzi, Silvio Danese, Sofie Berg, Joel Petersson, Jen-Fue Maa, Ezequiel Neimark, Jean-Frederic Colombel

SUSTAINED RESOLUTION OF EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH CROHN?S DISEASE RECEIVING ADALIMUMAB

Edouard Louis, Robert Löfberg, Walter Reinisch, David A Schwartz, Jen-Fue Maa, Sofie Berg, Bidan Huang, Anthony W. Wang, Anne M. Robinson, Brandee L Pappalardo

Item 1 - 4 / 4
1